Table 2. Characteristics of pre-nivolumab treatments.

	Sunitinib	Pazopanib
Median duration of metastatic disease (months)	21.1	18.9
Median duration of first-line treatment (months)	2.6	2.0
Response rates of first-line treatment
Complete response rate	5%	─
Partial response rate	22%	30%
Objective response rate	27%	30%
Stable disease rate	25%	15%
Progressive disease rate	48%	55%
Median duration of second-line treatment (months)	8.7	9.8
Response rates of second-line treatment
Complete response rate	─	3%
Partial response rate	30%	43%
Objective response rate	30%	46%
Stable disease rate	30%	20%
Progressive disease rate	40%	34%